3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
2
Phase 3
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Plasma cell
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Advanced Solid Tumors
4
Squamous Cell Carcinoma of Head and Neck
3
Carcinoma, Renal Cell
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Esophageal Neoplasms
2
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Solid Tumor, Unspecified, Adult
1
Solid Tumor
1
Pharyngeal Neoplasms
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Multiple Myeloma
1
Mouth Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Head and Neck Neoplasms
1
Erythrocytosis, Familial, 4
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Merkel Cell
1
Interventions
pembrolizumab
28
Cisplatin
24
Oxaliplatin
22
Irinotecan
22
Fluorouracil
22
Capecitabine
20
Leucovorin
17
Paclitaxel
16
Cyclophosphamide
14
Trastuzumab
12
Nivolumab
11
Carboplatin
11
Gemcitabine
10
Bevacizumab
10
Docetaxel
9
fludarabine
8
aldesleukin
8
S 1 (combination)
8
Ramucirumab
7
130-nm albumin-bound paclitaxel
7
atezolizumab
6
Albumin-Bound Paclitaxel
6
Taxes
5
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Biopsy
5
veliparib
4
tislelizumab
4
spartalizumab
4
dehydroftorafur
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1
×
Stomach Neoplasms
×
zimberelimab
×
Clear all
NCT05891171
2026-03-31
ARC-25
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
40 enrolled
NCT04772989
2025-08-28
ARC-12
Arcus Biosciences, Inc.
Phase 1
Completed
94 enrolled